Regulus Therapeutics (RGLS) Sees Unusually-High Trading Volume

Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) saw strong trading volume on Friday . 326,500 shares changed hands during mid-day trading, a decline of 62% from the previous session’s volume of 863,167 shares.The stock last traded at $1.18 and had previously closed at $1.20.

Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Tuesday, October 10th. Leerink Swann assumed coverage on shares of Regulus Therapeutics in a report on Friday. They set an “outperform” rating and a $2.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday, December 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $2.46.

The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77. The firm has a market cap of $128.90, a price-to-earnings ratio of -0.93 and a beta of 1.55.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantitative Investment Management LLC purchased a new position in shares of Regulus Therapeutics during the second quarter valued at approximately $103,000. GSA Capital Partners LLP purchased a new position in shares of Regulus Therapeutics during the second quarter valued at approximately $139,000. Royal Bank of Canada raised its holdings in shares of Regulus Therapeutics by 12.1% during the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 19,934 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $347,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Regulus Therapeutics by 189.1% during the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 240,890 shares during the last quarter. 59.39% of the stock is owned by hedge funds and other institutional investors.

WARNING: This piece of content was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3127648/regulus-therapeutics-rgls-sees-unusually-high-trading-volume.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.